Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up

KARAKAYA, MUHAMMED; özer, sevil; Kalkan, Cagdas; Tuzun, E.; Caliskan, Aysun; Keskin, ONUR; Kabacam, Gokhan; KARATAYLI, ERSİN; Karatayli, Ersin; Bozdayi, A.; Idilman, Ramazan; Yurdaydin, Cihan

doi:10.3851/imp3144

Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up

KARAKAYA M. F., özer s., Kalkan C., Tuzun E. A., Caliskan A., Keskin O., ...Daha Fazla

ANTIVIRAL THERAPY, cilt.22, sa.7, ss.559-570, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 7
Basım Tarihi: 2017
Doi Numarası: 10.3851/imp3144
Dergi Adı: ANTIVIRAL THERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.559-570
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Finite treatment of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) with nucleoside/nucleotide analogues (NAs) is important in resource-limited countries. Outcome of treatment discontinuation in patients on long-term lamivudine (LVD) was assessed in a single centre observational pilot study in the current study.